Forimtamig

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Multiple MyelomaRelapsed or Refractory Multiple Myeloma

Phase 1

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

CompletedNCT04557150

Hoffmann-La RocheMultiple Myeloma

Start: 2020-11-11End: 2026-03-17Updated: 2026-04-13

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

CompletedNCT06055075

Hoffmann-La RocheRelapsed or Refractory Multiple Myeloma

Start: 2023-12-12End: 2025-07-08Updated: 2025-07-14

Related Papers

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma

Blood Advances2026-09-16

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Clinical Pharmacology & Therapeutics2026-06-17

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood2024-10-3022 citations

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Blood2023-11-0212 citations

Abstract 843: Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myeloma

Cancer Research2023-04-042 citations

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Blood2022-11-1586 citations

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood2022-11-158 citations

Novel 17-Plex Flow Cytometry Assay for Comprehensive Immunophenotyping and Characterization of Plasma Cells (PC) in Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients

Blood2022-11-15

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

HemaSphere2022-06-0118 citations

S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere2022-06-011 citations